| Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis J Stone, H Fraser, AG Lim, JG Walker, Z Ward, L MacGregor, A Trickey, ... The Lancet Infectious Diseases 18 (12), 1397-1409, 2018 | 208 | 2018 |
| The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study A Trickey, H Fraser, AG Lim, A Peacock, S Colledge, JG Walker, J Leung, ... The lancet Gastroenterology & hepatology 4 (6), 435-444, 2019 | 189 | 2019 |
| Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis C Arum, H Fraser, AA Artenie, S Bivegete, A Trickey, M Alary, ... The Lancet public health 6 (5), e309-e323, 2021 | 127 | 2021 |
| The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom M Hickman, C Steer, K Tilling, AG Lim, J Marsden, T Millar, J Strang, ... Addiction 113 (8), 1461-1476, 2018 | 116 | 2018 |
| Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination AG Lim, H Qureshi, H Mahmood, S Hamid, CF Davies, A Trickey, N Glass, ... International journal of epidemiology 47 (2), 550-560, 2018 | 90 | 2018 |
| Larger mammalian body size leads to lower retroviral activity A Katzourakis, G Magiorkinis, AG Lim, S Gupta, R Belshaw, R Gifford PLoS pathogens 10 (7), e1004214, 2014 | 57 | 2014 |
| HTLV-I infection: a dynamic struggle between viral persistence and host immunity AG Lim, PK Maini Journal of theoretical biology 352, 92-108, 2014 | 52 | 2014 |
| Modelling the role of Tax expression in HTLV-I persistence in vivo MY Li, AG Lim Bulletin of mathematical biology 73, 3008-3029, 2011 | 48 | 2011 |
| Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway CF Aas, JH Vold, R Gjestad, S Skurtveit, AG Lim, KV Gjerde, EM Løberg, ... Substance abuse treatment, prevention, and policy 16, 1-10, 2021 | 38 | 2021 |
| Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis AG Lim, JG Walker, N Mafirakureva, GG Khalid, H Qureshi, H Mahmood, ... The Lancet Global Health 8 (3), e440-e450, 2020 | 34 | 2020 |
| Aiming at the global elimination of viral hepatitis: challenges along the care continuum A Heffernan, E Barber, NA Cook, AI Gomaa, YX Harley, CR Jones, ... Open forum infectious diseases 5 (1), ofx252, 2018 | 32 | 2018 |
| Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway CF Aas, JH Vold, S Skurtveit, AG Lim, S Ruths, K Islam, JE Askildsen, ... Substance abuse treatment, prevention, and policy 15, 1-12, 2020 | 31 | 2020 |
| Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study JG Walker, T Kuchuloria, D Sergeenko, H Fraser, AG Lim, S Shadaker, ... The Lancet Global Health 8 (2), e244-e253, 2020 | 24 | 2020 |
| Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: a modelling study A Trickey, H Fraser, AG Lim, JG Walker, A Peacock, S Colledge, J Leung, ... Journal of viral hepatitis 26 (12), 1388-1403, 2019 | 17 | 2019 |
| Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis A Artenie, J Stone, H Fraser, D Stewart, C Arum, AG Lim, AL McNaughton, ... The lancet Gastroenterology & hepatology, 2023 | 16 | 2023 |
| Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from … CF Aas, JH Vold, S Skurtveit, I Odsbu, F Chalabianloo, AG Lim, ... Substance abuse treatment, prevention, and policy 15, 1-10, 2020 | 16 | 2020 |
| Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO A Artenie, N Luhmann, AG Lim, H Fraser, Z Ward, J Stone, L MacGregor, ... The Lancet Gastroenterology & Hepatology 7 (4), 353-366, 2022 | 15 | 2022 |
| Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: a mathematical model JJ Ong, L Ruan, AG Lim, CS Bradshaw, D Taylor-Robinson, M Unemo, ... EClinicalMedicine 33, 2021 | 13 | 2021 |
| Evaluating FIML and multiple imputation in joint ordinal-continuous measurements models with missing data AJM Lim, MWL Cheung Behavior Research Methods, 1-15, 2021 | 11 | 2021 |
| Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons AG Lim, J Stone, B Hajarizadeh, M Byrne, GM Chambers, NK Martin, ... Hepatology 74 (5), 2366-2379, 2021 | 10 | 2021 |
